Rapsomaniki

Prognostic models for stable coronary artery disease based on electronic health

record cohort of 102,023 patients

eTable2 Baseline characteristics of stable coronary artery disease patients included in the study.

Baseline characteristics	ALL	Stable angina	Other CHD	Stable after	Stable after	Stable after	Stable after MI
N	102,023	45,645	21,915	13,325	4,700	6,818	9,620
Age, mean (SD), y	68.9 (12.8)	68.2 (13.0)	70.2 (11.2)	68.5 (13.7)	66.0 (13.2)	71.8 (13.1)	68.9 (13.5)
Females, %	44,523 (43.6%)	23,281 (51.0%)	7,977 (36.4%)	6,058 (45.5%)	1,303 (27.7%)	2,560 (37.5%)	3,344 (34.8%)
White ethnicity, %	77,802 (94.2%)	33,344 (93.4%)	16,371 (94.7%)	10,691 (94.0%)	3,968 (95.7%)	5,746 (95.7%)	7,682 (95.4%)
In most deprived quintile, %	20,361 (20.0%)	9,139 (20.0%)	4,200 (19.2%)	2,902 (21.8%)	941 (20.0%)	1,250 (18.3%)	1,929 (20.1%)
CVD RISK FACTORS							
Non-smoker	23,134 (33.4%)	10,831 (36.5%)	4,212 (27.9%)	2,717 (33.1%)	1,367 (32.6%)	2,451 (40.1%)	1,556 (26.2%)
Ex-smoker	23,872 (34.5%)	9,825 (33.1%)	5,365 (35.6%)	2,995 (36.5%)	1,182 (28.2%)	2,265 (37.1%)	2,240 (37.7%)
Current smoker	22,203 (32.1%)	9,024 (30.4%)	5,500 (36.5%)	2,486 (30.3%)	1,649 (39.3%)	1,394 (22.8%)	2,150 (36.2%)
SBP, mean (SD), mmHg	139.8 (22.3)	144.1 (21.8)	140.4 (21.3)	138.5 (22.1)	127.4 (20.5)	132.5 (21.5)	132.9 (22.8)
DBP, mean (SD), mmHg	78.9 (12.0)	81.3 (11.9)	78.6 (11.3)	78.1 (11.9)	74.1 (11.5)	74.5 (12.0)	76.2 (12.1)
Hypertension	75,159 (73.7%)	34,041 (74.6%)	18,316 (83.6%)	9,580 (71.9%)	2,565 (54.6%)	4,921 (72.2%)	5,736 (59.6%)
Diabetes	14,421 (14.1%)	5,926 (13.0%)	3,361 (15.3%)	1,995 (15.0%)	523 (11.1%)	1,273 (18.7%)	1,343 (14.0%)
Total chol, mean (SD), mmol/L	4.7 (1.2)	5.0 (1.2)	4.7 (1.1)	4.5 (1.1)	4.0 (1.0)	4.1 (1.0)	4.3 (1.0)
HDL mean (SD), mmol/L	1.3 (0.4)	1.4 (0.4)	1.3 (0.4)	1.3 (0.4)	1.2 (0.3)	1.3 (0.4)	1.3 (0.4)
BMI, median (IQR), kg/m2	27.9 (5.4)	27.6 (24.4-31.3)	27.0 (24.2-30.3)	27.5 (24.5-31.2)	26.7 (24.1-29.9)	26.9 (23.9-	26.9 (24.0-30.0)
CVD CO-MORBIDITIES							
Prior MI	20,694 (20.3%)	338 (0.7%)	10,636 (48.5%)	3,008 (22.6%)	1,188 (25.3%)	2,387 (35.0%)	3,137 (32.6%)
Peripheral arterial disease	8,923 (8.7%)	3,008 (6.6%)	2,288 (10.4%)	1,356 (10.2%)	395 (8.4%)	973 (14.3%)	903 (9.4%)
Heart failure	26,194 (25.7%)	10,639 (23.3%)	6,326 (28.9%)	4,012 (30.1%)	756 (16.1%)	2,196 (32.2%)	2,265 (23.5%)
Atrial fibrillation	15,887 (15.6%)	6,602 (14.5%)	3,099 (14.1%)	2,348 (17.6%)	587 (12.5%)	1,649 (24.2%)	1,602 (16.7%)
Stroke	9,799 (9.6%)	3,796 (8.3%)	2,216 (10.1%)	1,535 (11.5%)	298 (6.3%)	885 (13.0%)	1,069 (11.1%)
NON-CVD COMORBIDITIES							
Chronic kidney disease	7,006 (6.9%)	2,763 (6.1%)	1,212 (5.5%)	930 (7.0%)	415 (8.8%)	1,135 (16.6%)	551 (5.7%)
COPD	23,956 (23.5%)	10,903 (23.9%)	4,632 (21.1%)	3,599 (27.0%)	971 (20.7%)	1,735 (25.4%)	2,116 (22.0%)
Cancer	9,236 (9.1%)	3,971 (8.7%)	2,000 (9.1%)	1,242 (9.3%)	426 (9.1%)	810 (11.9%)	787 (8.2%)
Chronic liver disease	1,002 (1.0%)	430 (0.9%)	149 (0.7%)	175 (1.3%)	57 (1.2%)	98 (1.4%)	93 (1.0%)
Rheumatoid arthritis	5,028 (4.9%)	2,210 (4.8%)	1,023 (4.7%)	694 (5.2%)	227 (4.8%)	442 (6.5%)	432 (4.5%)
Hypothyroidism	7,298 (7.2%)	3,384 (7.4%)	1,461 (6.7%)	1,030 (7.7%)	265 (5.6%)	577 (8.5%)	581 (6.0%)
Hyperthyroidism	2,030 (2.0%)	921 (2.0%)	426 (1.9%)	302 (2.3%)	66 (1.4%)	151 (2.2%)	164 (1.7%)
PSYCHOSOCIAL							
Depression	17,040 (16.7%)	8,045 (17.6%)	3,151 (14.4%)	2,523 (18.9%)	757 (16.1%)	1,179 (17.3%)	1,385 (14.4%)
Anxiety	7,978 (7.8%)	3,714 (8.1%)	1,459 (6.7%)	1,195 (9.0%)	329 (7.0%)	556 (8.2%)	725 (7.5%)
BIOMARKERS							
Heart rate, mean (SD), beats/min	71.9 (14.8)	73.6 (15.1)	71.3 (14.2)	72.0 (15.0)	67.4 (13.0)	70.3 (14.5)	70.3 (14.9)
Creatinine, mean (SD), µmol/L	100.6 (33.0)	96.9 (31.1)	102.6 (32.6)	100.9 (33.6)	100.2 (28.5)	107.8 (39.4)	106.8 (35.1)
White cell count, mean (SD), 10^9/L	7.5 (2.3)	7.4 (2.3)	7.5 (2.3)	7.5 (2.3)	7.7 (2.3)	7.7 (2.4)	7.8 (2.4)
Haemoglobin, mean (SD), g/dL	13.4 (1.7)	13.5 (1.6)	13.5 (1.7)	13.3 (1.7)	13.6 (1.6)	13.0 (1.8)	13.3 (1.8)
GGT, mean (SD), units/L	41.9 (33.7)	41.3 (33.5)	41.3 (33.6)	43.9 (35.8)	42.3 (31.7)	41.5 (33.3)	43.4 (34.7)
HbA1c, mean (SD), %	7.3 (1.6)	7.3 (1.6)	7.3 (1.6)	7.4 (1.6)	7.1 (1.5)	7.3 (1.5)	7.3 (1.6)
MEDICATIONS/ INTERVENTIONS[1]							
PCI last 6 months	10,554 (10.3%)	778 (1.7%)	2,357 (10.8%)	1,147 (8.6%)	2,205 (46.9%)	1,961 (28.8%)	2,106 (21.9%)
CABG last 6 months	4,600 (4.5%)	1,583 (3.5%)	666 (3.0%)	533 (4.0%)	276 (5.9%)	622 (9.1%)	920 (9.6%)
Short-acting nitrates	39,044 (38.3%)	13,978 (30.6%)	9,120 (41.6%)	5,709 (42.8%)	2,543 (54.1%)	3,351 (49.1%)	4,343 (45.1%)
Long-acting nitrates	29,451 (28.9%)	11,109 (24.3%)	7,544 (34.4%)	5,075 (38.1%)	919 (19.6%)	2,190 (32.1%)	2,614 (27.2%)
Statins	80,672 (79.1%)	32,152 (70.4%)	18,615 (84.9%)	10,373 (77.8%)	4,587 (97.6%)	6,425 (94.2%)	8,520 (88.6%)
Aspirin	85,334 (83.6%)	35,135 (77.0%)	19,452 (88.8%)	11,038 (82.8%)	4,495 (95.6%)	6,413 (94.1%)	8,801 (91.5%)
Clopidogrel	88,556 (86.8%)	81,618 (80%)	88,145 (86.4%)	93,861 (92%)	99,880 (97.9%)	98,758 (96.8%)	96,718 (94.6%)
On ≥1 BP-lowering drugs[2]	95,169 (93.3%)	41,603 (91.1%)	20,860 (95.2%)	12,126 (91.0%)	4,625 (98.4%)	6,672 (97.9%)	9,283 (96.5%)
Thiazides	41,091 (40.3%)	20,480 (44.9%)	8,120 (37.1%)	5,229 (39.2%)	1,323 (28.1%)	2,687 (39.4%)	3,252 (33.8%)
Beta-blockers	71,723 (70.3%)	29,048 (63.6%)	15,785 (72.0%)	9,422 (70.7%)	4,133 (87.9%)	5,655 (82.9%)	7,680 (79.8%)
ARBs/ACEI	71,610 (70.2%)	28,689 (62.9%)	15,276 (69.7%)	8,835 (66.3%)	4,501 (95.8%)	6,151 (90.2%)	8,158 (84.8%)
Calcium-channel blockers	56,719 (55.6%)	25,768 (56.5%)	13,157 (60.0%)	8,006 (60.1%)	1,732 (36.9%)	3,575 (52.4%)	4,481 (46.6%)
Loop diuretics	43,457 (42.6%)	17,595 (38.5%)	9,998 (45.6%)	6,254 (46.9%)	1,603 (34.1%)	3,451 (50.6%)	4,556 (47.4%)

Abbreviations: ARB, angiotensin-receptor blockers; ACEI, angiotensin-converting-enzyme inhibitor; BP, blood pressure; SCAD, stable coronary artery disease; CC, complete cases; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein cholesterol; STEMI, ST-segment elevation MI; SBP, systolic blood pressure.

[1] Medications are provided for descriptive purposes and were not included in the models

[2] Includes ARBs/ACEI, beta-blockers and calcium-channel blockers